Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 334.5 GBX 2.45% Market Closed
Market Cap: 354.6m GBX

Wall Street
Price Targets

OXB Price Targets Summary
Oxford BioMedica PLC

Wall Street analysts forecast OXB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OXB is 526.32 GBX with a low forecast of 383.8 GBX and a high forecast of 840 GBX.

Lowest
Price Target
383.8 GBX
15% Upside
Average
Price Target
526.32 GBX
57% Upside
Highest
Price Target
840 GBX
151% Upside
Oxford BioMedica PLC Competitors:
Price Targets
BIOCON
Biocon Ltd
18% Upside
VRTX
Vertex Pharmaceuticals Inc
16% Upside
377740
BioNote Inc
14% Upside
TSHA
Taysha Gene Therapies Inc
161% Upside
MDGL
Madrigal Pharmaceuticals Inc
56% Upside
IMMX
Immix Biopharma Inc
247% Upside
301080
Acrobiosystems Co Ltd
6% Upside
ACAD
ACADIA Pharmaceuticals Inc
25% Upside

Revenue
Forecast

Revenue Estimate
Oxford BioMedica PLC

For the last 13 years the compound annual growth rate for Oxford BioMedica PLC's revenue is 24%. The projected CAGR for the next 3 years is 25%.

24%
Past Growth
25%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Oxford BioMedica PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Oxford BioMedica PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OXB's stock price target?
Price Target
526.32 GBX

According to Wall Street analysts, the average 1-year price target for OXB is 526.32 GBX with a low forecast of 383.8 GBX and a high forecast of 840 GBX.

What is Oxford BioMedica PLC's Revenue forecast?
Projected CAGR
25%

For the last 13 years the compound annual growth rate for Oxford BioMedica PLC's revenue is 24%. The projected CAGR for the next 3 years is 25%.

Back to Top